Mild renal dysfunction is associated with electrocardiographic left ventricular hypertrophy

American Journal of Hypertension

Volumn 18, Issue 3, 2005, Pages 342-347

  Smilde, Tom D J ^a   Asselbergs, Folkert W ^a   Hillege, Hans L ^a   Voors, Adriaan A ^a   Kors, Jan A ^b   Gansevoort, Ron T ^a   Van Gilst, Wiek H ^a   De Jong, Paul E ^a   Van Veldhuisen, Dirk J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Left ventricular hypertrophy; Microalbuminuria; PREVEND; Renal function

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE CLASSIFICATION; ELECTRIC POTENTIAL; ELECTROCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NETHERLANDS; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 15744395854     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2004.09.015     Document Type: Article

References (21)

1. F.H. Messerli Hypertension and sudden cardiac death Am J Hypertens 12 1999 181S 188S
2. A.M. Gerdes Cardiac myocyte remodeling in hypertrophy and progression to failure J Card Fail 8 2002 S264 S268
3. B.A. Vakili, P.M. Okin, R.B. Devereux Prognostic implications of left ventricular hypertrophy Am Heart J 141 2001 334 341
4. A.X. Garg, W.F. Clark, R.B. Haynes, A.A. House Moderate renal insufficiency and the risk of cardiovascular mortality results from the NHANES I Kidney Int 61 2002 1486 1494
5. G. Leoncini, F. Viazzi, D. Parodi, S. Vettoretti, E. Ratto, M. Ravera, C. Tomolillo, M. Del Sette, G.P. Bezante, G. Deferrari, R. Pontremoli Mild renal dysfunction and subclinical cardiovascular damage in primary hypertension Hypertension 42 2003 14 18
6. R. Pontremoli, C. Nicolella, F. Viazzi, M. Ravera, A. Sofia, V. Berruti, G.P. Bezante, M. Del Sette, C. Martinoli, G. Sacchi, G. Deferrari Microalbuminuria is an early marker of target organ damage in essential hypertension Am J Hypertens 11 1998 430 438
7. V. Palmieri, R.P. Tracy, M.J. Roman, J.E. Liu, L.G. Best, J.N. Bella, D.C. Robbins, B.V. Howard, R.B. Devereux Relation of left ventricular hypertrophy to inflammation and albuminuria in adults with type 2 diabetes the Strong Heart Study Diabetes Care 26 2003 2764 2769
8. J.D. Harnett, P.S. Parfrey, S.M. Griffiths, M.H. Gault, P. Barre, R.D. Guttmann Left ventricular hypertrophy in end-stage renal disease Nephron 48 1988 107 115
9. S.J. Pinto-Sietsma, W.M. Janssen, H.L. Hillege, G. Navis, D. de Zeeuw, P.E. de Jong Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population J Am Soc Nephrol 11 2000 1882 1888
10. K/DOQI clinical practice guidelines for chronic kidney disease evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative Am J Kidney Dis 39 2002 S1 S246
11. B. Dahlof, R. Devereux, U. de Faire, F. Fyhrquist, T. Hedner, H. Ibsen, S. Julius, S. Kjeldsen, K. Kristianson, O. Lederballe-Pedersen, L.H. Lindholm, M.S. Nieminen, P. Omvik, S. Oparil, H. Wedel The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group Am J Hypertens 10 1997 705 713
12. A. Levin, C.R. Thompson, J. Ethier, E.J. Carlisle, S. Tobe, D. Mendelssohn, E. Burgess, K. Jindal, B. Barrett, J. Singer, O. Djurdjev Left ventricular mass index increase in early renal disease impact of decline in hemoglobin Am J Kidney Dis 34 1999 125 134
13. H.L. Hillege, W.H. van Gilst, D.J. van Veldhuisen, G. Navis, D.E. Grobbee, P.A. de Graeff, D. de Zeeuw Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition the CATS randomized trial Eur Heart J 24 2003 412 420
14. W.F. Terpstra, J.F. May, A.J. Smit, P.A. de Graeff, H.J. Crijns Microalbuminuria is related to marked end organ damage in previously untreated, elderly hypertensive patients Blood Press 11 2002 84 90
15. N.D. Vaziri, Z. Ni, F. Oveisi, K. Liang, R. Pandian Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insufficiency Hypertension 39 2002 135 141
16. H. Buter, G. Navis, R.P. Dullaart, D. de Zeeuw, P.E. de Jong Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM Nephrol Dial Transplant 16 2001 771 775
17. K. Suzuki, K. Kato, O. Hanyu, O. Nakagawa, Y. Aizawa Left ventricular mass index increases in proportion to the progression of diabetic nephropathy in type 2 diabetic patients Diabetes Res Clin Pract 54 2001 173 180
18. B. Dahlof, R.B. Devereux, S.E. Kjeldsen, S. Julius, G. Beevers, U. Faire, F. Fyhrquist, H. Ibsen, K. Kristiansson, O. Lederballe-Pedersen, L.H. Lindholm, M.S. Nieminen, P. Omvik, S. Oparil, H. Wedel Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) a randomised trial against atenolol Lancet 359 2002 995 1003
19. B.M. Brenner, M.E. Cooper, D. de Zeeuw, W.F. Keane, W.E. Mitch, H.H. Parving, G. Remuzzi, S.M. Snapinn, Z. Zhang, S. Shahinfar Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 2001 861 869
20. A.S. Apakkan, B. Ozmen, D. Ozmen, Z. Parildar, B. Senol, S. Habif, I. Mutaf, N. Turgan, O. Bayindir Serum and urinary nitric oxide in type 2 diabetes with or without microalbuminuria relation to glomerular hyperfiltration J Diabetes Complications 17 2003 343 348
21. P.A. McCullough, K.R. Sandberg Chronic kidney disease and sudden death strategies for prevention Blood Purif 22 2004 136 142